Selective PRMT5 Inhibitor Scaffold for Off-Target Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for the development of small molecules that can effectively inhibit the activity of protein arginine methyltransferase 5 (PRMT5) to address diseases such as proliferative disorders, metabolic disorders, and blood disorders, as PRMT5 plays a significant role in epigenetic regulation and is associated with genetic alterations.
Innovation Solution
Compounds described by the formula (I) and their pharmaceutically acceptable salts are developed to inhibit PRMT5 activity, offering selectivity and efficacy in inhibiting PRMT5 over other methyltransferases, and are used in pharmaceutical compositions to treat PRMT5-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are developed to inhibit PRMT5 activity, then therapeutic efficacy against PRMT5-mediated disorders is improved, but selectivity over other methyltransferases may be compromised
Solution Approach 1:
The patent employs local quality by designing compounds with specific structural features (Formula I) that create localized interaction zones within the PRMT5 active site. The molecular structure includes specific substituents (R1-R8, Ar, L groups) that form precise local interactions with PRMT5 residues, enhancing selectivity while maintaining inhibitory efficacy. This localized molecular design allows differentiation between PRMT5 and other methyltransferases through targeted structural complementarity.
Solution Approach 2:
The patent applies parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations in Formula I) to optimize the balance between PRMT5 inhibition potency and selectivity. By adjusting chemical parameters such as aromatic group substitutions, linker lengths, and functional group orientations, the compounds achieve enhanced specificity for PRMT5 while minimizing off-target effects on related enzymes.
2Reliability
If compounds with high PRMT5 inhibition potency are designed, then disease treatment effectiveness is improved, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments defined in Formula I: aromatic core structures (Ar), linker regions (L), and substituent groups (R1-R8). This modular segmentation allows systematic optimization of each region's contribution to binding affinity while maintaining overall structural manageability. The segmented design facilitates structure-activity relationship studies and rational drug design.
Solution Approach 2:
The patent employs universality by designing a core molecular scaffold (Formula I) that can accommodate multiple substituent variations while maintaining the essential PRMT5 binding interactions. This universal framework allows a single compound series to target PRMT5 effectively across different disease contexts, with the ability to adjust substituents for optimal potency without redesigning the entire molecular architecture.
Data Source
AI summary
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.